| |
|
|
Session 64
Poster Presentations Drug-Drug Interactions Wednesday 1:30 - 3:30 pm Hall A |
| 533 | Didanosine and Tenofovir DF Drug-drug Interaction: Assessment of Didanosine Dose Reduction B. P. Kearney*, E. Isaacson, J. Sayre, H. Namini, A. Cheng Gilead Sci, Inc, Foster City, CA |
| 534 | Lack of Interaction between Stavudine Extended-release Formulation and Tenofovir Disoproxil Fumarate S. Kaul*1, K. Bassi1, B. Damle1, R. Smith1, J. Gale1, E. O'Mara1, U. Chaudhari2, K. Ryan3 1Bristol-Myers Squibb Pharm Res Inst (BMSPRI), Princeton, NJ; 2BMSPRI, Hamilton, NJ; and 3Bristol-Myers Squibb Virology Med Affairs, Plainsboro, NJ |
| 535 | A Two-way Drug Interaction Between Lopinavir/Ritonavir and Phenytoin M. L. Lim*1, S. S. Min1, J. J. Eron1, R. Bertz2, M. Robinson2, A. Gaedigk3, A. D. M. Kashuba1 1Univ of North Carolina, Chapel Hill; 2Abbott Labs, Abbott Park, IL; and 3Children's Mercy Hosp, Kansas City, MO |
| 536 | Assessment of the Multiple-dose Pharmacokinetic Interaction of Lopinavir/Ritonavir with Nelfinavir C. Klein, R. Bertz*, E. Ashbrenner, T. Chira, L. Williams, A. Hsu, B. Bernstein Abbott Labs, Abbott Park, IL |
| 537 | Pharmacokinetic Parameters of Atazanavir/Ritonavir when Combined to Tenofovir in HIV Infected Patients with Multiple Treatment Failures: A Sub-study of Puzzle2-ANRS 107 Trial A. M. Taburet*1, C. Piketty2, L. Gérard3, I. Vincent1, C. Chazallon3, F. Clavel4, V. Calvez5, J. P. Aboulker3, P.M Girard6 1Hosp Bicêtre, Paris, France; 2Hosp G Pompidou, Paris, France; 3INSERM, Villejuif, France; 4Hosp Bichat, Paris, France; 5Hosp Pitié Salpétrière, Paris, France; and 6Hosp St Antoine, Paris, France |
| 538 | Pharmacokinetics and Pharmacodynamics of Low-dose Mycophenolate Mofetil in Early Stage HIV-infected Patients Successfully Treated with HAART J. Martorell1, M. Brunet1, F. García1, G. Mestre*1, M. Plana1, A. Libois1, T. Gallart1, T. Pumarola1, J. Miró1, J. L. Blanco1, E. Martínez1, J. Mallolas1, J. Lange2, G. Pantaleo3, J. M Gatell1 1Inst d'Investigacions Biomèdiques August Pi i Sunyer, Hosp Clin, Univ of Barcelona, Spain; 2Intl Antiviral Therapy Eval Ctr, Amsterdam, The Netherlands; and 3Lab of AIDS Immunopathogenesis, Hosp de Baeumont Lausanne, Switzerland |
| 539 | Mycophenolate Mofetil Lowers Plasma Nevirapine Concentrations but Has No Effect on Intracellular Triphosphate Concentrations S. Sankatsing*1,2, P. Hoggard3, D. Back3, S. Kewn3, A. Huitema4, K. Crommentuyn4, J. Beijnen4, J. Lange1,2, J. Prins2 1Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 2Academic Med Ctr, Amsterdam, The Netherlands; 3Univ of Liverpool, UK; and 4Slotervaart Hosp, Amsterdam, The Netherlands |
| 540 | Two-year Evaluation of the Interactions between Antiretroviral Medication and Cyclosporine in HIV+ Liver and Kidney Transplant Recipients L.A. Frassetto*, M. Baloum, M.E. Roland, L. Carlson, P. Stock, L.Z. Benet Univ of California at San Francisco |
| 541 | Enfuvirtide: Investigations on the Drug Interaction Potential in HIV-infected Patients M. Boyd*1, K. Ruxrungtham1, X. Zhang2, E. Bellibas2, N. E. Buss3, I. H. Patel2 1HIV Netherlands Australia Thailand Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 2Roche, Nutley, NJ; and 3Roche, Basel, Switzerland |
| 542 | Pharmacokinetic Interaction between Rifampin and the Twice-daily Combination of Indinavir and Low-dose Ritonavir in HIV-infected Patients U. Justesen*1, A. Andersen2, N. Klitgaard3, K. Brosen1, J. Gerstoft2, C. Pedersen3 1Univ of Southern Denmark, Odense, Denmark; 2RigsHospet, Copenhagen, Denmark; and 3Odense Univ Hosp, Denmark |
| 543 | Atazanavir: A Summary of Two Pharmacokinetic Drug Interaction Studies in Healthy Subjects D. Tackett*1, M. Child1, S. Agarwala1, M. Geiger1, M. Geraldes1, B. Laura2, E. O'Mara1 1Bristol-Myers Squibb Pharm Res Inst, Princeton, NJ and 2Greenways Fndn, Inc, Evansville, IN |
| 544 | Pharmacokinetics of Nelfinavir (Viracept 250 mg tablet): Effect of Food Intake on Single-dose PK Parameters C. Petersen*1, E. Pun1, R. Strada1, E. Daniels 1, C. Bramson2, E. Randinitis2 1Agouron Pharmaceuticals, Inc, a Pfizer Co, La Jolla, CA and 2Pfizer Global RandD, Ann Arbor, MI |
| 545 | The Effect of Ethanol on Protease Inhibitor Exposure in Chronic Heavy Ethanol Users F. Aweeka*1, P. Lizak1, L. Karan1, B. Kosel2, S. Au1, M. Weiner1, M. Lu1 1Univ of California at San Francisco and 2Univ of Washington, Seattle |
| 546 | High Indinavir Plasma Concentrations in HIV-1 Patients Co-infected with Hepatitis B or C Virus Receiving Indinavir and Ritonavir Low Dosages: A GENOPHAR Substudy P. Bossi1, G. Peytavin*2, C. Lamotte2, H. Ait-Mohand1, M. Bonmarchand1, N. Ktorza1, A. Simon1, C. Delagerre1, V. Calvez1, F. Bricaire1, D. Costagliola1, C. Katlama1 1Pitié-Salpêtrière Hosp, Paris, France and 2Bichat-Claude Bernard Hosp, Paris, France |